These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37804290)

  • 21. Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis.
    Han Y; Yuan X; Hu X; Fang Y; Jiang M; Feng H; Gao L
    Cardiol J; 2023; 30(4):556-566. PubMed ID: 35912712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial.
    Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombotic vs. Bleeding Events of Interruption of Dual Antiplatelet Therapy within 12 Months among Patients with Stent-Driven High Ischemic Risk Definition following PCI.
    Wang HY; Xu B; Song CX; Guan CD; Xie LH; Zhao YY; Cai ZX; Yuan S; Dou KF
    J Interv Cardiol; 2022; 2022():3895205. PubMed ID: 35095347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P2Y
    Gragnano F; Mehran R; Branca M; Franzone A; Baber U; Jang Y; Kimura T; Hahn JY; Zhao Q; Windecker S; Gibson CM; Kim BK; Watanabe H; Song YB; Zhu Y; Vranckx P; Mehta S; Hong SJ; Ando K; Gwon HC; Calabrò P; Serruys PW; Dangas GD; McFadden EP; Angiolillo DJ; Heg D; Valgimigli M;
    J Am Coll Cardiol; 2023 Feb; 81(6):537-552. PubMed ID: 36754514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.
    Serruys PW; Takahashi K; Chichareon P; Kogame N; Tomaniak M; Modolo R; Chang CC; Komiyama H; Soliman O; Wykrzykowska JJ; de Winter RJ; Ferrario M; Dominici M; Buszman P; Bolognese L; Tumscitz C; Benit E; Stoll HP; Hamm C; Steg PG; Onuma Y; Jüni P; Windecker S; Vranckx P; Colombo A; Valgimigli M
    Eur Heart J; 2019 Aug; 40(31):2595-2604. PubMed ID: 31397487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second-Generation Drug-Eluting Stents: The Veterans Affairs Extended DAPT Study.
    Kinlay S; Young MM; Sherrod R; Gagnon DR
    J Am Heart Assoc; 2023 Jan; 12(2):e027055. PubMed ID: 36645075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome.
    Wang HY; Mo R; Guan CD; Wang Y; Zhao YY; Xie LH; Zhang R; Cai ZX; Xu B; Dou KF
    Catheter Cardiovasc Interv; 2022 Jan; 99(1):98-113. PubMed ID: 33909311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial.
    Watanabe H; Morimoto T; Natsuaki M; Yamamoto K; Obayashi Y; Ogita M; Suwa S; Isawa T; Domei T; Yamaji K; Tatsushima S; Watanabe H; Ohya M; Tokuyama H; Tada T; Sakamoto H; Mori H; Suzuki H; Nishikura T; Wakabayashi K; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T;
    JAMA Cardiol; 2022 Apr; 7(4):407-417. PubMed ID: 35234821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioabsorbable polymer drug-eluting stents with 4-month dual antiplatelet therapy versus durable polymer drug-eluting stents with 12-month dual antiplatelet therapy in patients with left main coronary artery disease: the IDEAL-LM randomised trial.
    van Geuns RJ; Chun-Chin C; McEntegart MB; Merkulov E; Kretov E; Lesiak M; O'Kane P; Hanratty CG; Bressollette E; Silvestri M; Wlodarczak A; Barragan P; Anderson R; Protopopov A; Peace A; Menown I; Rocchiccioli P; Onuma Y; Oldroyd KG
    EuroIntervention; 2022 Apr; 17(18):1467-1476. PubMed ID: 35285803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention: 3-Year Follow-up of the SMART-CHOICE Randomized Clinical Trial.
    Choi KH; Park YH; Song YB; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Oh JH; Chun WJ; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Gwon HC; Hahn JY;
    JAMA Cardiol; 2022 Nov; 7(11):1100-1108. PubMed ID: 36169938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of outcomes in patients with or without ARC-HBR criteria undergoing PCI with polymer-free biolimus coated stents: The BioFreedom France study.
    Garot P; Brunel P; Dibie A; Morelle JF; Abdellaoui M; Levy R; Carrié D; Karsenty B; Robin C; Berland J; Copt S; Sadozai Slama S; Oldroyd K; Morice MC; Lipiecki J;
    Catheter Cardiovasc Interv; 2023 Jan; 101(1):60-71. PubMed ID: 36378683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population.
    Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation].
    Xu JJ; Zhu P; Song Y; Yuan DS; Jia SD; Zhao XY; Yao Y; Jiang L; Xu N; Li JX; Zhang Y; Song L; Gao LJ; Chen JL; Qiao SB; Yang YJ; Xu B; Gao RL; Yuan JQ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 May; 50(5):450-457. PubMed ID: 35589593
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial.
    Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY
    Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Mauri L; Kirtane AJ; Windecker S; Yeh RW; Dauerman HL; Price MJ; Christen T; Allocco DJ; Meredith IT; Kereiakes DJ
    Am Heart J; 2018 Nov; 205():110-117. PubMed ID: 30218844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial.
    Landi A; Heg D; Frigoli E; Vranckx P; Windecker S; Siegrist P; Cayla G; Włodarczak A; Cook S; Gómez-Blázquez I; Feld Y; Seung-Jung P; Mates M; Lotan C; Gunasekaran S; Nanasato M; Das R; Kelbæk H; Teiger E; Escaned J; Ishibashi Y; Montalescot G; Matsuo H; Debeljacki D; Smits PC; Valgimigli M;
    JACC Cardiovasc Interv; 2023 Apr; 16(7):798-812. PubMed ID: 37045500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of over-2-year dual antiplatelet therapy on the rate of major adverse cardiac and cerebral events for everolimus-eluting stent implantation: The landmark analysis from Tokyo-MD PCI registry.
    Ueshima D; Ashikaga T; Yoshikawa S; Sasaoka T; Hatano Y; Kurihara K; Maejima Y; Isobe M
    J Cardiol; 2017 Jun; 69(6):815-822. PubMed ID: 27692568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy.
    Valgimigli M; Frigoli E; Vranckx P; Ozaki Y; Morice MC; Chevalier B; Onuma Y; Windecker S; Delorme L; Kala P; Kedev S; Abhaichand RK; Velchev V; Dewilde W; Podolec J; Leibundgut G; Topic D; Schultz C; Stankovic G; Lee A; Johnson T; Tonino PAL; Klotzka A; Lesiak M; Lopes RD; Smits PC; Heg D;
    J Am Coll Cardiol; 2022 Aug; 80(8):766-778. PubMed ID: 35981821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of 6- versus 12-month dual antiplatelet therapy on clinical prognosis in patients with high bleeding risk: Insights from the 4-year results of the I LOVE IT 2 study.
    Zhang J; Qiu M; Na K; Ma S; Jiang Z; Li J; Li Y; Han Y
    Catheter Cardiovasc Interv; 2021 May; 97 Suppl 2():1025-1031. PubMed ID: 33645914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.